Clinical Trials Logo

Clinical Trial Summary

This is a study of ATG-037 Monotherapy and Combination Therapy with Pembrolizumab in Patients with Locally Advanced or Metastatic Solid Tumors


Clinical Trial Description

This is a Phase I, Multi-center, Open-label, and Dose-finding Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG-037 Monotherapy and Combination Therapy with Pembrolizumab in Patients with Locally Advanced or Metastatic Solid Tumors. Number of subjects : 1. 39-51 subjects for Dose escalation phase part 1 2. Maximum of 18 subjects or Dose escalation phase part 2 3. 24-34 subjects per Dose expansion cohort ;


Study Design


Related Conditions & MeSH terms

  • Locally Advanced or Metastatic Solid Tumors
  • Neoplasms

NCT number NCT05205109
Study type Interventional
Source Antengene Corporation
Contact Sunny He
Phone 187 2152 1865
Email sunny.he@antengene.com
Status Recruiting
Phase Phase 1
Start date June 7, 2022
Completion date February 28, 2028

See also
  Status Clinical Trial Phase
Recruiting NCT04564417 - First-In-Human (FIH) Study of W0180 as Single Agent and in Combination With Pembrolizumab in Adults With Locally Advanced or Metastatic Solid Tumors Phase 1
Recruiting NCT04511845 - A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion). Phase 1
Active, not recruiting NCT04128423 - Study of AMV564 in Subjects With Advanced Solid Tumors Phase 1
Recruiting NCT05012618 - A Dose-escalation Study of LUNA18 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion). Phase 1
Recruiting NCT05581004 - A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors Phase 1
Completed NCT03736850 - Study of CS3006 in Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1
Recruiting NCT05137275 - Study of Anti-5T4 CAR-raNK Cell Therapy in Locally Advanced or Metastatic Solid Tumors Early Phase 1
Completed NCT01021748 - A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010) Phase 1
Completed NCT01713036 - Oral Bioavailability and Mass Balance Trial With Pimasertib Phase 1
Recruiting NCT05116709 - Assessment of Safety and Preliminary Clinical Efficacy With BAT6005 in Advanced Malignant Solid Tumors Phase 1
Recruiting NCT05102214 - HLX301 (TIGIT×PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03478995 - Study to Evaluate Safety and Tolerability of GX-I7 in Patients With Locally Advanced or Metastatic Solid Tumors Phase 1
Active, not recruiting NCT05830539 - IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients Phase 1/Phase 2
Active, not recruiting NCT05360381 - HLX35(EGFR×4-1BB Bispecific) in Patients With Advanced or Metastatic Solid Tumors Phase 1
Completed NCT03150810 - Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT05957471 - Study of BC3195 Monotherapy in Patients With Advanced Solid Tumors Phase 1
Terminated NCT03565991 - Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors Phase 2
Completed NCT02722954 - A Phase 1b Study of Demcizumab Plus Pembrolizumab in Locally Advanced or Metastatic Solid Tumors Phase 1
Active, not recruiting NCT02478099 - MPDL3280A-treatment-IST-UMCG Phase 2
Recruiting NCT05699811 - IFN╬▒ Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors Phase 1/Phase 2